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CASE REPORT Open Access
Substance-induced anxiety disorder after one
dose of 3,4-methylenedioxymethamphetamine:
a case report
Kaeley Kaplan1*, Fiona Kurtz1,2 and Kelly Serafini1
Abstract
Background: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after
a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary
Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and
treating this rare mental health disorder.
Case presentation: Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a
35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-
methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic
symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist
buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin
reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with
a behavioral health consultant, who provided psychoeducation on the experience of panic, building
relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary
care provider and behavioral health consultant facilitated the planning and enactment of the patient’s care
plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the
patient’s symptoms subsided. This improvement was attributed to the combination of the behavioral health
intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine
ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms
to date.
Conclusions: Our patient’s case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamine-
induced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver
individualized, timely mental health care in a primary care setting.
Keywords: Substance-induced anxiety disorder, 3,4-Methylenedioxymethamphetamine, MDMA, Selective
serotonin reuptake inhibitor, Mental health, Primary care
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Background
3,4-Methylenedioxymethamphetamine (MDMA), more
commonly known as “molly” in its pure form and as “ec-
stasy” historically, is a drug that gained popularity in the
1980s and continues to be used around the world [1, 2].
Current data suggest that MDMA use is prevalent in the
United States. According to the 2014 National Survey
on Drug Use and Health, approximately 609,000 people
over the age of 12 years had used MDMA in the previous
month, and among adults aged 26 years or older, 6.5%
reported lifetime use of MDMA, and 0.1% reported
MDMA use in the previous month [2]. Recreational
users have reported that the drug induces “feelings of
intimacy and closeness to others” and “positive mood”
[3, 4]. Acute (< 1 day) and subacute (1–7 days) negative
effects of the drug include confusion/delirium, loss of
appetite, insomnia, panic/anxiety, low mood/depression,
and difficulty concentrating, with low mood typically oc-
curring 3–4 days after MDMA use [4]. The longer-term
psychological effects of MDMA are more difficult to de-
fine, in part because many MDMA users are polydrug
users and in part because of the high prevalence of comor-
bid disorders such as depression, anxiety, and insomnia
[1]. Even less is known about the possible long-term ef-
fects of a one-time dose of MDMA, though several case
reports, including the present one, highlight lasting effects
after a single dose [5, 6].
The drug’s chief psychopharmacological target is the
monoaminergic system, which plays a role in emotional
regulation and physiological arousal [1, 7]. Research in
rodents and nonhuman primates has consistently dem-
onstrated an MDMA-triggered release of dopamine, nor-
epinephrine, and serotonin from nerve terminals [7, 8].
Repeated doses of MDMA lead to damage of serotonergic
nerve terminals, perhaps via increasing free radical activ-
ity, and there is concern and some clinical evidence for
long-term depletion of serotonin and changes to the sero-
tonergic neural network in heavy users of MDMA [1, 7].
Alterations in serotonergic activity have long been
implicated in anxiety disorders, and feelings of panic/
hyperarousal are induced by increased activity of epineph-
rine and norepinephrine, adding strength to the hy-
pothesis that MDMA use can elicit anxiety and panic
symptoms [9].
Patients’ concerns regarding illicit substance use (e.g.,
MDMA use) and mental health are increasingly addressed
and treated in the primary care setting. Primary care facil-
ities provide an easily accessible and comfortable space to
discuss a wide range of medical and psychiatric concerns
[10]. In fact, 50–70% of people experiencing psychological
or behavioral conditions receive their treatment in pri-
mary care settings from primary care providers (PCPs)
[11, 12], and 80% of individuals with a mental health dis-
order report that they will visit their PCP at least one time
within a calendar year [13]. Thus, PCPs are the most likely
health care providers to assess and treat substance use
concerns.
Recently, some pioneering medical clinics have begun
to adopt a Primary Care Behavioral Health (PCBH)
model with the aim of strengthening integration between
physical and mental health care. This approach is par-
ticularly applicable to and beneficial in treating patients
with depression, anxiety, posttraumatic stress disorder,
and substance use disorder symptoms or concerns. These
patients often benefit from both psychopharmacological
and behavioral health treatment. The PCBH model has a
population-based health focus and aims to meet the be-
havioral health needs of all patients receiving medical
treatment in primary care, including those who are more
likely to experience barriers to specialty mental health care
because of cost, language differences, stigma, and trans-
portation difficulties [14]. Arguably one of the greatest
benefits of this integrated model is strengthened commu-
nication between mental health providers (commonly re-
ferred to as behavioral health consultants) and medical
care providers [14]. This enhanced communication fa-
cilitates unification of psychopharmacological and behavioral
health interventions and maximizes opportunities for PCPs
to receive treatment feedback, particularly with unique
cases. Given the novelty and complexity of substance-
induced psychiatric disorders, patients may benefit greatly
from the high level of communication and coordination
afforded by the PCBH model.
In this case report, we describe a patient who took a
single dose of MDMA that triggered substance-induced
anxiety disorder which lasted for several months. The
patient’s symptoms gradually improved and remitted
with a combination of medical and behavioral therapy in
a primary care office that had adopted principles of the
PCBH model. The PCP and behavioral health consultant
worked closely together and with the patient in pro-
viding comprehensive mental health care. This case
report highlights both an uncommon presentation of
substance-induced anxiety disorder and a unique ap-
proach to integrative mental health treatment.
Case presentation
A previously healthy 35-year-old Hispanic man with a
remote history of mild performance anxiety in late ado-
lescence presented to our family medicine residency
clinic to establish and seek care for acute onset of anx-
iety. The patient was a manager at a large manufacturing
firm and had received a master’s degree. At the time of
presentation, he was married with two children. He had
no family history of mental illness and was not taking
prescription medications. At his initial visit at the clinic,
he reported that 9 days prior, he had taken one dose of
“molly” while at a gathering with friends. The friend
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who had supplied the drug stated that it was “pure
crystal MDMA.” According to the patient, this was his
first lifetime use of MDMA. He had also consumed sev-
eral alcoholic drinks that night, reportedly reaching the
level of intoxication. He described having a “fine” ex-
perience with the drug and returned to his normal
baseline for the next 2 days. On the third day after
ingesting MDMA, he began to experience an increase
in worry and agitation; he reported having panicked
thoughts and development of palpitations, blurry vision,
flushing, increased thirst, and insomnia. He stated that
these symptoms increased over the coming days, prompt-
ing him to seek medical care. Regarding substance use his-
tory, the patient reported occasional social alcohol use
since his early 20s, rarely to excess. He had used cannabis
several times while in college (ages 18–22) and found that
this precipitated anxiety and therefore he did not continue
using it regularly. He denied any regular use of other illicit
substances.
On the initial day that the patient met with a medical
provider in the clinic, he reported a score of 20 (max-
imum score of 21) on the Generalized Anxiety Disorder
7-item scale [15], an anxiety screening and rating tool
commonly used in primary care offices. This score was
consistent with a severe level of anxiety. The patient was
prescribed buspirone, a serotonin 1A receptor (5-HT1A)
receptor agonist, with a plan to uptitrate to 15 mg twice
daily over the coming weeks. The patient was also referred
to the clinic’s behavioral health service for adjunctive
treatment and was promptly seen by a behavioral health
consultant for their first session the following day. This
initial visit involved an assessment of his biopsychosocial
history and mood, a functional analysis of his anxiety
symptoms, and a collaborative discussion regarding his
treatment goals. Using interventions informed by cogni-
tive behavioral therapy, the patient and the behavioral
health consultant aimed to increase his coping skills and
management of his anxiety symptoms and to improve his
overall quality of life (e.g., reduce distress, increase enjoy-
ment at home, and increase productivity at work).
The patient was seen for follow-up every 7–10 days by
his PCP for the next month (see Table 1). Simultan-
eously, he received behavioral health treatment each
week following his first month of medical treatment in
the family medicine clinic. He then established a thera-
peutic relationship with a counselor outside the clinic,
where they reportedly engaged in talk therapy weekly.
The patient reported only a slight improvement in his
anxiety and panic symptoms despite the therapeutic
dose buspirone; therefore, he was prescribed a selective
serotonin reuptake inhibitor (SSRI) and a benzodiazep-
ine and was referred to the psychiatry department for
additional consultation. The consulting psychiatrist was
concerned for MDMA-induced anxiety disorder and rec-
ommended discontinuation of buspirone and initiation
of low-dose sertraline with slow uptitration. The patient
benefited from behavioral health treatment specifically
aimed at enhancing understanding and controlling the
sympathetic nervous system (i.e., cognitive behavioral
modeling, psychoeducation on the cycle of panic, and
relaxation skill training). Behavioral health treatment
was especially important as he awaited the clinical effect
of his psychoactive medications.
Ongoing evaluation by the PCP, a consulting psych-
iatrist, and the behavioral health consultant supported a
diagnosis of substance-induced anxiety disorder. He expe-
rienced persistent anxiety (reporting daily worry, panic,
racing heart, dizziness, restlessness, and catastrophic
Table 1 Patient presentation and treatment timeline
Day 0 Patient reports having ingested MDMA
Day 3 Development of acute anxiety and physiological arousal
Day 9 Patient presents to clinic for evaluation and is prescribed uptitration of buspirone
Week 2 Patient is prescribed lorazepam
Week 3 Patient is taking full dose of buspirone with no significant improvement in anxiety; rare lorazepam use
Prescribed SSRI but does not start taking
First visit with behavioral health consultant, total of six visits every 1–4 weeks
Week 4 Seen by psychiatrist and given tentative diagnosis of substance-induced anxiety disorder
SSRI recommended
Week 6 Begins SSRI sertraline and begins buspirone taper
Week 7 Reports some improvement in anxiety and sleep
Week 7.5 Reports acute worsening of anxiety with suicidal ideation
Sertraline dose is lowered, and in 3 days, patient no longer has suicidal ideation
Weeks 8–10 Continues sertraline, reaching dose of 50 mg once daily with continued improvement in anxiety
Weeks 10+ Seen by psychiatrist 2, who concurs with diagnosis of substance-induced anxiety disorder
Patient continues sertraline 50 mg/day for several more months without resurgence of anxiety symptoms
MDMA 3,4-Methylenedioxymethamphetamine, SSRI Selective serotonin reuptake inhibitor
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thinking), and all of his symptoms developed shortly
after ingesting a single dose of MDMA. His symptoms
caused him significant distress and impairment in his
employment as well as his family life. The patient de-
nied clinically significant anxiety directly prior to taking
MDMA; his only history of anxiety was performance
anxiety many years prior. Therefore, he did not meet
criteria for panic disorder or generalized anxiety dis-
order, because his symptom onset followed substance
ingestion. Simultaneously, the patient reported trans-
diagnostic depressive symptoms, including hopeless-
ness, fatigue, maladaptive thinking, and low mood.
These symptoms, which also began following the pa-
tient’s use of MDMA, were etiologically attributed to
his anxious physiological symptoms and thoughts, in
particular the catastrophic and generalized worries that
this one-time drug use had “ruined” his life. Conse-
quently, his symptoms appeared to be explained by the
substance-induced anxiety, as opposed to representing
a discrete depressive disorder.
The patient initially tolerated the sertraline well and
experienced a relatively rapid improvement in anxiety
symptoms while taking 25 mg daily. After 8 days of the
25-mg dose, the dose was increased to 37.5 mg. After 2
days at this dose, the patient developed abrupt onset of
suicidal ideation with a resurgence of anxiety and panic
symptoms. Given the gravity of these new symptoms,
the PCP and behavioral health consultant worked to-
gether and with the patient to devise a plan for ongoing
care. He was able to see the behavioral health consultant
for an urgent visit. The dose of sertraline was reduced to
25 mg, and plans were made for intensive outpatient
mental health treatment at a nearby hospital.
While awaiting entrance into that program, his suicidal
ideation and anxiety abated. As his symptoms improved,
the behavioral health consultant supplemented sympa-
thetic nervous system training with thought identification
and cognitive retraining. These interventions served to ad-
dress his reported catastrophic and demoralizing ap-
praisals following the use of MDMA (e.g., “I am a terrible
person for taking that Molly,” and “I have ruined my life
forever”). He saw a second psychiatrist for additional rec-
ommendations. They concurred with the diagnosis of
substance-induced anxiety disorder and the prescribed
SSRI treatment. Eventually, the dose of sertraline was
slowly increased to 50 mg with continued improvement
in all symptoms and no further resurgence of suicidal
ideation. The patient’s anxiety and panic were not well
controlled until approximately 2.5 months after ingest-
ing MDMA. At 6 months following his presentation, he
was doing well with a plan to slowly taper the sertra-
line. He expressed gratitude for an interdisciplinary
team approach and the unique benefits of skills training
in tandem with psychopharmacological treatment.
Discussion
In our patient, a single dose of MDMA triggered anxiety
that lasted nearly 2.5 months and eventually improved
with the implementation of both psychopharmacological
and behavioral health techniques. We know of only one
other case report in which one dose of MDMA was re-
ported to precipitate protracted anxiety and/or panic
symptoms [5], though given the general underreporting
of illicit substance use, the true number may be higher.
Clinicians should consider recent MDMA use as a po-
tential etiology of acute anxiety.
Substance-induced mental health disorders are challen-
ging not only to diagnose but also to treat, particularly
given the complex nature of substance interactions and
overall patient presentation. In our patient, the diagnosis
of substance-induced anxiety disorder was corroborated
by three separate practitioners (a behavioral health con-
sultant and two independent psychiatrists). The patient
had denied any significant precipitants that may have trig-
gered his anxiety, and there was a consistent temporal re-
lationship between MDMA ingestion and his symptoms.
Although the treating providers had no reason to doubt
the patient’s stated history of one-time MDMA use, it is
possible that he unknowingly had ingested other or add-
itional substances. The treating providers did not employ
a urine drug screen during the course of the patient’s
evaluation and treatment, chiefly because few substances
can be reliably detected 9 days postingestion. Therefore,
the patient’s MDMA use must be taken at face value as
the cause of his symptoms.
Medically speaking, initial treatment with the 5-HT1A
receptor agonist buspirone was not effective in relieving
the patient’s anxiety and should have been reserved as
an adjunctive treatment to an SSRI-based treatment
regimen, not as sole therapy. Offering a benzodiazepine
at the first visit may have helped the patient more quickly
gain control of his anxiety (it was not prescribed until the
second visit), though benzodiazepines can interfere with
cognitive behavioral therapy and should be deployed with
caution owing to concerns surrounding dependence and
abuse. It was not until uptitration of the SSRI sertraline
that the patient began to experience consistent symptom-
atic improvement. Notably, this patient did experience a
brief worsening of his anxiety while initiating sertraline;
this is a relatively common and well-known side effect of
SSRIs. In this case, the patient’s acute worsening of symp-
toms lasted only a few days. Many psychotropic therapies
take weeks to months to take effect, and a key component
of the patient’s care was timely access to mental health
care that served to alleviate symptoms while awaiting the
therapeutic effect of medications.
The PCBH model served to offer collaborative, inter-
disciplinary care that treated both his short-term and
long-term needs. The patient’s acute needs were met by
Kaplan et al. Journal of Medical Case Reports  (2018) 12:142 Page 4 of 5
psychopharmacological treatment aimed at reducing
his debilitating physiological panic and anxiety symp-
toms. The providers were able to offer long-term bene-
fits by tailoring a behavioral health treatment plan that
helped the patient modify newly exacerbated maladap-
tive thought patterns (cognitive retraining) as well as
develop long-term behavioral skills to manage his
physiological symptoms (relaxation training).
His overall treatment was bolstered by adherence to
the PCBH model’s recommendation of frequent, efficient,
and consistent communication between multidisciplinary
team members [14]. Use of this approach prevented delays
in the patient’s treatment and enhanced treatment plan
development and agreement among team members. The
PCBH model has been found to be effective for treating
patients across the entire spectrum of mental health con-
ditions [10]. The present case report corroborates such
findings and demonstrates the feasibility and benefits of
integrating behavioral and primary medical care [14]. The
PCBH model offers the advantage of combining the re-
sources and knowledge of multiple providers in a single,
unified, and accessible setting.
Conclusions
This report describes a rare presentation of substance-
induced anxiety disorder after ingestion of a single dose
of MDMA. The patient’s symptoms were severe and
were addressed with a combination of behavioral health
and psychopharmacological therapies. His symptoms
stabilized and improved only after several months of be-
havioral health counseling and medical treatment with
the SSRI sertraline. We posit that his care was augmented
by the direct integration of his medical treatment with
his behavioral health treatment according to the PCBH
model. This integration allowed for timely communica-
tion between the patient’s behavioral health provider
and PCP and facilitated the assessment and treatment
of his unique mental health disorder.
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